Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) EBT Margin (2017 - 2025)

Historic EBT Margin for Organogenesis Holdings (ORGO) over the last 9 years, with Q3 2025 value amounting to 14.03%.

  • Organogenesis Holdings' EBT Margin rose 89700.0% to 14.03% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.33%, marking a year-over-year increase of 19300.0%. This contributed to the annual value of 0.58% for FY2024, which is 29800.0% down from last year.
  • According to the latest figures from Q3 2025, Organogenesis Holdings' EBT Margin is 14.03%, which was up 89700.0% from 11.72% recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' EBT Margin ranged from a high of 17.19% in Q2 2021 and a low of 29.74% during Q1 2025
  • For the 5-year period, Organogenesis Holdings' EBT Margin averaged around 2.6%, with its median value being 7.04% (2023).
  • As far as peak fluctuations go, Organogenesis Holdings' EBT Margin surged by 362600bps in 2021, and later crashed by -257900bps in 2025.
  • Organogenesis Holdings' EBT Margin (Quarter) stood at 14.77% in 2021, then plummeted by -49bps to 7.58% in 2022, then tumbled by -124bps to 1.8% in 2023, then soared by 549bps to 8.1% in 2024, then soared by 73bps to 14.03% in 2025.
  • Its EBT Margin was 14.03% in Q3 2025, compared to 11.72% in Q2 2025 and 29.74% in Q1 2025.